Navigation Links
Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntington's Disease Model
Date:9/16/2008

8 in the online version of the Proceedings of the National Academy of Sciences.

"The marked reduction in symptoms achieved in the Huntington's disease model without overt toxicity defines a second disease target for our HDAC inhibitor program," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation. "We plan to continue to evaluate the utility of our novel HDAC inhibitors as a potential treatment for both Friedreich's ataxia and Huntington's disease."

Huntington's disease is caused by a trinucleotide repeat expansion in the Huntington's disease gene (Htt) that results in production of a mutant misfolded protein that is unable to function correctly. Huntington's disease is characterized by dysregulation in the transcription of hundreds of genes in the brain, leading to Huntington's symptoms ranging from jerky and random movements to impaired thinking and perception. Huntington's disease is a familial disease, passed from parent to child through a mutation in the normal gene. Symptoms of Huntington's disease typically emerge between the ages of 30 and 50 and fall into three categories: motor, cognitive and psychiatric. Cognitive symptoms include slowed processing of information in the brain, resulting in communication and planning difficulties, while depression is the most common psychiatric symptom of Huntington's disease. Motor symptoms include lack of coordination, muscle spasms, and chorea. As the disease progresses, any function requiring muscle control is affected, leading to severe disability, incapacitation or loss of life due to complications 10 to 20 years after symptoms first appear. There are approximately 30,000 people in the United States with Huntington's disease and there is currently no safe and effective treatment for the disease.

Repligen licensed the exclusive rights to intellectual property covering HDAC inhibitors from The Scripps Research Institute in April 2007 following which Repligen estab
'/>"/>

SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... MISSISSAUGA, ON , April 23, 2015 /CNW/ ... major sustainable packaging award from North ... Packaging,s Brandcheck Competitor Comparison won Silver in the ... Awards. The Brandcheck "Competitor Comparison" is ... set of North American and Global peers. This ...
(Date:4/23/2015)... California (PRWEB) April 23, 2015 ... diagnostics refer to a series of genetic tests ... cystic fibrosis, Lou Gehrig's disease, Huntington's disease, and ... examining the gene composition and interaction in diseased ... disease as well as the response to treatment, ...
(Date:4/23/2015)... (PRWEB) April 23, 2015 ... in Personalized Medicine, is excited to announce the ... profile . This profile assesses 62 genetic variations ... dosing information for commonly prescribed non-opioid pain medications, ... name Neurontin), alprazolam (brand name Xanax) and acetaminophen ...
(Date:4/23/2015)... 2015 Delpor, Inc. (Delpor), a biotechnology ... United States Patent and Trademark Office has issued 2 ... technology. US Pat. No. 8,986,727 was issued on ... delivery device for the sustained release of therapeutic ... the sustained (zero-order) release of large and small molecules ...
Breaking Biology Technology:Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 2Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 3Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 2Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 3Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3
... 2011 Cumberland Pharmaceuticals Inc. (NASDAQ: ... care and gastroenterology markets, today announced third quarter 2011 financial ... months ended September 30, 2011, net revenue was $13.1 million, ... growth in net revenue was driven by an increase in ...
... 2011 Cempra Pharmaceuticals will be presenting data ... (MRSA) strains isolated from cystic fibrosis (CF) ... human lung epithelial in vitro model ... Conference in Anaheim, California.  Both studies will be ...
... 3, 2011 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... Product Development at BioMarin, will present a company update at ... 10, 2011 at 3:30 p.m. MST.   Interested ... call via the investor section of the BioMarin website, ...
Cached Biology Technology:Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 2Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 3Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 4Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 5Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 6Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 7Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 8Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 9Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 10Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 11Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 12Taksta™ (fusidic acid) Demonstrates Activity Against MRSA Isolated From Cystic Fibrosis Patients 2Taksta™ (fusidic acid) Demonstrates Activity Against MRSA Isolated From Cystic Fibrosis Patients 3BioMarin to Present at the Credit Suisse Healthcare Conference 2
(Date:4/1/2015)... April 1, 2015   Medisafe ™, the leading ... across iOS and Android smartphones ... biofeedback into the platform to allow patients to track ... the first time, patients will be able to visualize ... impacts important biometrics, such as glucose levels and blood ...
(Date:3/31/2015)... , March 31, 2015   Guidepoint , a ... of the Post-Surgical Pain Management TRACKER, part of the ... usage trends in the medical device and therapeutics markets. ... data including treatment volumes, market share, and adoption rates ... associated with joint surgery. The Post-Surgical Pain ...
(Date:3/26/2015)... March 26, 2015 The Granite ... recreation and athletic club, today announced it has implemented ... freedom of movement for members and staff, while restricting ... comprehensive process, we selected FST,s IMID Access system because ... for our members and staff, in addition to unparalleled ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2
... study performed at Children,s Hospital Los Angeles found no evidence ... nerve hypoplasia (ONH). Their results are reported in the ... ( AAPOS ). ONH, an underdevelopment of optic ... an isolated abnormality or as part of a group of ...
... study published online in the journal PLOS Pathogens , ... single amino acid they could change the sugar to which ... cells. The BK polyomavirus lost the ability to bind its ... its cousin SV40 polyomavirus, which is active in monkeys. ...
... Research Careers) Program has announced the travel award recipients ... VA from October 31-November 3, 2013. These awards are ... postdoctorates and scientists into the mainstream of the basic ... postdocs and new assistant professors. This year MARC conferred ...
Cached Biology News:No evidence to support stem cell therapy for pediatric optic nerve hypoplasia 2No evidence to support stem cell therapy for pediatric optic nerve hypoplasia 3Single mutation gives virus new target 2MARC travel awards announced for 2013 Institute on Teaching and Mentoring 2
Imject Freund's Incomplete Adjuvant (FIA)...
With sodium bicarbonate. Sterile, Cell culture tested...
A substrate for all AChE-based EIA kits....
... gel stain was developed specifically for reduced mutagenicity ... staining DNA in agarose or acrylamide gels. SYBR ... ethidium bromide but SYBR Safe stain's detection sensitivity ... Safe stain comes as a premixed solution that ...
Biology Products: